Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sumitomo Dainippon

Novartis day

Novartis licenses Ophthotech eye drug in $1bn deal

Fovista is a potential first-in-class treatment for wet AMD

TxCell plans listing as EU biotech wakes up to IPOs

Move follows UK allergy therapy developer Circassia's listing

- PMLiVE

Galapagos divests CRO operations to pursue biotech path

Sells Argenta and BioFocus to Charles River Laboratories for up to €134m

- PMLiVE

2013 – biotech boomed

The $10bn-plus strategic acquisition returned and pharma companies sought to replenish their pipelines

- PMLiVE

Incubating biotech’s future

The trials of nurturing the next generation of small to medium-sized biotechnology firms

- PMLiVE

BIA elects six new board members

Biotech trade body adds representatives from MedImmune, J&J and more

- PMLiVE

New arrivals join BioHub at AZ’s Alderley Park

Six new biopharma start-ups set up at the UK biocluster

- PMLiVE

Bioclusters benefit from pharma shake-up

Sweeping job cuts at Europe’s largest drugmakers in recent years have spread gloom through the pharma sector, but the release of talent is helping to drive the development of bioclusters

- PMLiVE

Amgen and Onyx agree $10.4bn takeover deal

Deal provides indication of the premium big biopharma will pay to replenish pipelines

- PMLiVE

AZ adds to pipeline again with Amplimmune buy

Pharma company pays $500m via its MedImmune subsidiary for the small US biotech

Biotech threatened by UK drug pricing changes, says BIA

It says VBP will undermine the attractiveness of the sector for investors

- PMLiVE

Fresenius sells biotech business

Germany company's biotechnology arm picked up by Neopharm owners

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links